Did Bristol Myers Squibb deliberately drag its feet with Breyanzi’s FDA application to avoid paying former Celgene shareholders $6.4 billion? A federal judge found no proof of that intent. | Did Bristol Myers Squibb deliberately dragged its feet with Breyanzi’s FDA application to avoid paying former Celgene shareholders $6.4 billion? A federal judge found no proof of that intent. But as Mizuho analyst Salim Syed noted, BMS’ legal battle around the CVR is far from over.
